1. HBW Insight
  2. >>Beauty
  3. >>Innovation & IP

L'Oreal, Lauder Optimistic About Innovations In Challenging 2017 Climate

 
• By Ryan Nelson

The pure-play beauty leaders continue to grow in a challenging global climate, both looking to recent and upcoming launches to keep them on an upward trajectory.

Innovation concept presented by a consultant in management on webinar screen

L'Oreal S.A. and Estee Lauder Companies, Inc. highlighted innovations during recent earnings calls that they expect to drive continued growth in a global climate where consumer spending has been markedly sluggish of late.

The pure-play beauty leaders have been faring better in the current environment than some of their more diversified peers. Notably,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation & IP

More from Beauty

ELC Veteran Returns To Lead Makeup, While C&D, Charlotte Tilbury Strike Promo Deals; Beauty Roundup

 
• By Eileen Francis

Lisa Sequino returns to Estee Lauder to lead the strategic direction and global growth of its makeup brands. Church & Dwight has signed up two-time Olympic Gymnast Jordan Chiles as an ambassador for its Hero Cosmetics skincare brand. Plus more beauty news in brief.

Beauty Industry: Counter Impact Of State Legislation By Connecting With Lawmakers – IBA

 
• By Eileen Francis

Beauty stakeholders will undoubtedly feel the impact of new state laws targeting cosmetic ingredients and packaging and should therefore open lines of communication with state lawmakers.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.